Aside from effective antiretroviral therapy, there is no consistently effective antiparasitic therapy for cryptosporidiosis in AIDS. The purpose of this study was to assess safety, efficacy, and durability of combination therapy with paromomycin and azithromycin for chronic cryptosporidiosis. Patients with AIDS, chronic cryptosporidiosis, and õ100 CD4 cells/mL were treated with open-label paromomycin (1.0 g twice a day) plus azithromycin (600 mg once a day) for 4 weeks, followed by paromomycin alone for 8 weeks. In 11 patients, median stool frequency decreased from 6.5/day (baseline) to 4.9/day (week 4) and 3.0/day (week 12). Median reductions in 24-h oocyst excretion were 84%, 95%, and ú99% at 2, 4, and 12 weeks, respectively. None of the responses were attributable to antiretrovirals. Of 5 survivors at 12 -30 months of follow-up, 3 remain asymptomatic off medications, and 2 have chronic, mild diarrhea. Treatment of cryptosporidiosis with azithromycin and paromomycin was associated with significant reduction in oocyst excretion and some clinical improvement.
Cryptosporidium parvum, an intracellular protozoan parasite, AIDS-related cryptosporidiosis, azithromycin monotherapy has been ineffective [7, 8] . In clinical practice, azithromycin has is a frequent cause of chronic diarrhea in human immunodeficiency virus (HIV)-infected patients, resulting in significant frequently been used in combination with paromomycin for treatment of cryptosporidiosis [9] , but the safety and efficacy morbidity and mortality. Chronic cryptosporidiosis occurs when CD4 lymphocyte counts are õ180/mm 3 [1] . In many AIDS of this combination has not been carefully assessed. The purpose of this study was to obtain data on the safety, efficacy, patients, cryptosporidiosis resolves as immune status improves with antiretroviral therapy [2] . However, in patients in whom and durability of a combination regimen of paromomycin and azithromycin in the treatment of AIDS-related cryptosporiantiretroviral therapy fails and in developing countries where effective antiretroviral therapy is not available, cryptosporidiosis diosis. causes prolonged diarrhea and wasting. Treatment for chronic cryptosporidiosis in HIV-infected patients has been problematic. Paromomycin, a poorly absorbed aminoglycoside antibiotic, has Methods demonstrated some efficacy in the treatment of AIDS-related (defined as §3 loose stools/day on §5 days/week for §3 weeks), Despite treatment, however, relapse and subsequent biliary disand Cryptosporidium oocysts in their stools were screened for ease were common. Two small, placebo-controlled trials have enrollment. All patients with stool studies negative for other parabeen reported with conflicting results [4, 5] .
sites (including nonspecific fluorescent stain for microsporidia), Azithromycin, an azalide antibiotic, has also been used in bacterial enteric pathogens, and Clostridium difficile toxin and who human cryptosporidiosis [6] . However, in clinical trials for were not already being treated with aminoglycosides or macrolides were offered enrollment. Enrollees underwent baseline assessment of symptoms, including the number of stools per day and 24-h fecal excretion of Cryptosporidium oocysts. Subjects were treated increased in 1. One patient did not provide a baseline stool specimen and was evaluated for symptoms only. In our previCharacteristic ous study of patients treated with paromomycin alone [4] , median decrease in 24-h oocyst excretion at 2 weeks was only Age, years (range) 37 (23 -44) % male (no.)
91 (10) 50%, and oocysts were undetectable in only 1 of 9.
% white (no.) 55 (6) There were also significant reductions in stool frequency by % Hispanic (no.) 27 (3) weeks 4 and 12 (both P õ .05 vs. baseline). Of interest, the % black (no.) 18 (2) median 24-h stool weight actually increased during the first 4
Median CD4 cells/mm 3 (range) 30 (8 -55) weeks but decreased between weeks 4 and 12 (after azithro- the study period. The paromomycin/azithromycin combination was well toler-NOTE. Of 13 subjects enrolled, 1 withdrew immediately after enrollment and 1 was excluded due to no detectable oocysts in stool at baseline. ated, with only 2 of 11 (18%) discontinuing azithromycin early due to abdominal cramping. Two patients with persistent diarrhea discontinued paromomycin between weeks 4 and 12 with immediate resolution of the diarrhea, and a third experienced Primary analysis of efficacy was performed at week 4, and durability of response was assessed by a second analysis at week resolution of mild residual diarrhea with cessation of paromo-12. In addition, changes in stool weight, frequency, consistency, mycin after completion of the study. No drug interactions, and oocyst excretion and in patient Karnofsky score during the ototoxicity, or nephrotoxicity were noted. Also, no significant first 2 weeks of combination treatment were compared with those changes in serum albumin, alkaline phosphatase, body weight, from our previous study of patients treated with paromomycin or Karnofsky scores were seen.
alone [4] . At the end of the study period, therapy was continued After study completion, subjects were followed for up to 30 at the discretion of the primary care physician. Statistical analyses months. Five have survived, of whom 2 have chronic, mild were performed using the two-tailed Wilcoxon signed rank test. diarrhea and continue to take paromomycin and/or azithromycin, and 3 have experienced complete resolution of diarrhea off medications. Four of the 11 developed biliary disease. Two Results of these 4 died; the other 2 experienced marked relief of abdominal pain and, in 1, complete resolution of diarrhea after choleDuring the study period, 13 patients met inclusion criteria and all consented for enrollment. One withdrew immediately cystectomy for acalculous cholecystitis. Cryptosporidium was not found in either gallbladder. In 1, cytomegalovirus (CMV) after enrollment, and 1 was excluded due to no detectable oocysts in the stool at baseline. An additional patient did not inclusions were found; the other showed only nonspecific acalculous cholelithiasis on histopathology. provide a baseline stool specimen and was excluded from analyses of stool weight and oocyst quantitation. Baseline characSix patients have died, 3 from progressive diarrhea. In 1 of these, colonoscopy with biopsy revealed gastrointestinal CMV teristics are shown in table 1. All had advanced immunosuppression and chronic diarrhea. All but 1 had previously been inclusions, and biliary disease was also present. In another, CMV retinitis was documented and gastrointestinal CMV distreated with zidovudine. At baseline, only 4 of 11 were receiving antiretroviral therapy: 2 on stavudine monotherapy, 1 on ease suspected (no Cryptosporidium oocysts were detectable in the stool). The third refused endoscopy, and coinfection stavudine/lamivudine combination therapy, and 1 on stavudine/ lamivudine/indinavir (20 CD4 cells/mm 3 and HIV-1 plasma could not be excluded. Of the remaining 3 patients, 1 died of pancreatobiliary disease from suspected cryptosporidiosis, and viremia of ú100,000 copies/mL). Four of 11 patients remained off antiretroviral therapy, and 3 remained on stable antiretrovi-2 died from unrelated causes (body cavity lymphoma and suspected primary central nervous system lymphoma) ú1 year ral regimens throughout the study period. In 3 patients, stavudine monotherapy was initiated during weeks 2, 5, and 11. One after resolution of their diarrhea. patient, who was on stavudine/lamivudine at baseline, began indinavir at week 3; however, diarrhea and oocyst excretion Discussion had already resolved by week 2.
The major clinical and laboratory outcomes are summarized
In this small open-label study, treatment of cryptosporidiosis in AIDS with the combination of azithromycin and paromomyin table 2. The 24-h oocyst excretion decreased significantly by week 4 of paromomycin/azithromycin combination therapy, cin was associated with a dramatic reduction in oocyst excretion. The median decrease of 24-h oocyst excretion was 95% with further decreases between weeks 4 and 12 (both P õ .05 vs. baseline). The median decrease in oocyst excretion was by 4 weeks and ú99% at 12 weeks. Five of 9 and 6 of 10 patients had a §10-fold reduction in oocyst excretion by weeks 84% at week 2, 95% at week 4, and ú99% at week 12. By week 12, 24-h oocyst excretion was undetectable in 3 patients, 4 and 12, respectively. This contrasts with our previous study of paromomycin, in which there was a median reduction in ral therapy. During our study, most patients were on no antiretroviral therapy or nucleoside monotherapy, and there was no oocyst excretion of only 50% and only 3 of 9 had a reduction of ú1 log [4] . Previous studies of untreated patients have clear relationship between antiretroviral drugs and the responses noted. Only 2 of our patients were treated with protease shown some variability in oocyst excretion. When 24-h collections have been obtained and quantitated, the day-to-day variinhibitors, 1 in whom therapy failed and the other only after resolution of symptoms and oocyst excretion. ability in oocyst excretion is generally õ1 log [4, 11] . For example, of 40 patients in the placebo arm of a trial of bovine Previous studies with paromomycin alone have shown variable responses. Open-label and retrospective studies have shown anti-Cryptosporidium immunoglobulin, only 1 had ú1 log decrease in oocyst excretion [12] (Crabb J, ImmuCell, personal partial and complete responses in about two-thirds of patients [3] . Only two small placebo-controlled trials have been reported. communication). Thus, the changes noted here are well outside of the range expected from random variation in excretion.
In one, paromomycin was associated with a significant reduction in oocyst excretion and stool frequency compared with placebo Reduced oocyst excretion was associated with a decrease in stool frequency. By 12 weeks, 3 patients were asymptomatic [4] . The median decrease in oocyst excretion was only 50%. In the second study, responses were noted in 8 of 17 patients treated off medications, and 2 others had only mild diarrhea, easily controlled with antimotility agents along with azithromycin with paromomycin, a proportion that was not significantly different in the placebo group [5] . Dropouts, which only occurred and/or paromomycin. In 2 others, with acalculous cholecystitis (1 of whom was found to be coinfected with CMV), symptoms from the placebo arm, were excluded from analysis, and only patients with a reduction in stool frequency of §50% were resolved promptly after cholecystectomy. Three patients had progressive diarrhea. However, at least 2 of the 3 had active considered to have responded. Furthermore, oocyst excretion was only assessed in a semiquantitative method. Thus, the design CMV disease. One patient had resolution of diarrhea but died of progressive pancreatobiliary disease.
made it unlikely that the trial could have detected the modest efficacy noted in the first study. Improvements in oocyst excretion and stool frequency were not accompanied by consistent reductions in stool volume. DiAzithromycin has also been studied in AIDS patients with cryptosporidiosis. An open-label, expanded-access program arrhea is a recognized complication of therapy with azithromycin, even at doses significantly smaller than those used in noted clinical improvement in most patients but minimal changes in oocyst excretion [14] . In a placebo-controlled trial, this study. Stool volume decreased after discontinuation of that drug. Three patients noted clinical improvement when paromo-85 patients with AIDS and cryptosporidiosis were randomized to 900 mg of either azithromycin or placebo per day [7] . There mycin was discontinued. Diarrhea has not been previously reported with paromomycin therapy in cryptosporidiosis, but was no significant difference in stool frequency, oocyst shedding, or weight change. Post hoc analysis, however, suggested worsening of gastrointestinal function with paromomycin has been recognized [13] . If careful parasitologic measures had not a decreased oocyst excretion in the subjects with highest azithromycin levels. This association was not confirmed in been included in our study, drug side effects and coinfections might have been mistaken for treatment failure. studies with intravenous azithromycin, though there was a trend toward lower levels of alkaline phosphatase [15] . Combination While our results are encouraging, enthusiasm must be tempered by the lack of a placebo control group. Others have therapy with paromomycin/azithromycin has not been previously studied. noted dramatic responses of cryptosporidiosis to antiretroviral therapy. For example, Benhamou et al. [2] noted resolution of In summary, we noted a significant reduction in oocyst excretion and stool frequency in Cryptosporidium-infected AIDS symptoms in 14 patients with AIDS and cryptosporidiosis when they were started on protease inhibitor -containing antiretrovipatients receiving dual therapy with paromomycin and azithro-
